Using CDK2 inhibitors to prevent hearing loss caused by cancer treatment
CDK2 inhibitors for protecting hearing loss
['FUNDING_SBIR_2'] · TING THERAPEUTICS, INC. · NIH-11228819
This study is testing a new drug called TT001 to see if it can help prevent hearing loss in cancer patients who are receiving cisplatin chemotherapy, so they can keep their hearing while still getting the treatment they need.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TING THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (San Diego, UNITED STATES) |
| Trial ID | NIH-11228819 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a drug called TT001, which is a CDK2 inhibitor, to protect patients from hearing loss that can occur as a side effect of cisplatin, a common chemotherapy drug. The study involves testing the effectiveness of TT001 in preventing cell death in cochlear cells, which are crucial for hearing, while ensuring that it does not interfere with the cancer-fighting properties of cisplatin. Patients may benefit from this research as it aims to provide a solution for the significant number of cancer patients who experience hearing loss due to their treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving cisplatin treatment and are at risk of developing hearing loss.
Not a fit: Patients who are not undergoing cisplatin treatment or those who do not have a risk of hearing loss may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that prevents hearing loss in cancer patients undergoing cisplatin therapy.
How similar studies have performed: Previous research has shown promise in using CDK2 inhibitors for protecting against cell death, making this approach a potentially viable option.
Where this research is happening
San Diego, UNITED STATES
- TING THERAPEUTICS, INC. — San Diego, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUANG, YUNLONG — TING THERAPEUTICS, INC.
- Study coordinator: HUANG, YUNLONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents